



Corrigendum: Diplatin, a Novel and Low-Toxicity Anti-Lung Cancer Platinum Complex, Activation of Cell Death in Tumors via a ROS/JNK/p53-Dependent Pathway, and a Low Rate of Acquired Treatment Resistance

OPEN ACCESS

Edited and reviewed by:

Fabrizio Marcucci,
University of Milan, Italy

*Correspondence:

Yicheng Xie
ycxie@zju.edu.cn

†Present Address:

Xixi Lin,
The Second Affiliated Hospital and
Yuying Children's Hospital of Wenzhou
Medical University, Wenzhou, China

†These authors have contributed
equally to this work

Specialty section:

This article was submitted to
Pharmacology of Anti-Cancer Drugs,
a section of the journal
Frontiers in Pharmacology

Received: 07 March 2022

Accepted: 05 April 2022

Published: 28 April 2022

Citation:

Lin X, Jia Y, Dong X, Shen J, Jin Y, Li Y,
Wang F, Anenberg E, Zhou J, Zhu J,
Chen X, Xie Q and Xie Y (2022)
Corrigendum: Diplatin, a Novel and
Low-Toxicity Anti-Lung Cancer
Platinum Complex, Activation of Cell
Death in Tumors via a ROS/JNK/p53-
Dependent Pathway, and a Low Rate
of Acquired Treatment Resistance.
Front. Pharmacol. 13:890886.
doi: 10.3389/fphar.2022.890886

Xixi Lin^{1†‡}, Yongliang Jia^{2,3‡}, Xinwei Dong^{2,3}, Jian Shen^{2,3}, Yachao Jin³, Yanyou Li⁴,
Fang Wang⁵, Eitan Anenberg¹, Jiancang Zhou⁶, Jianping Zhu⁶, Xiaoping Chen⁴,
Qiangmin Xie^{1,2} and Yicheng Xie^{1*}

¹Children's Hospital, Zhejiang University School of Medicine, Hangzhou, China, ²Zhejiang Respiratory Drugs Research Laboratory of Food and Drug Administration of China, Zhejiang University School of Medicine, Hangzhou, China, ³Breath Smooth Biotech Hangzhou Co., LTD, Hangzhou, China, ⁴Beijing Shuobai Pharmaceutical Co., LTD, Beijing, China, ⁵Joinn Laboratories, BAD, Beijing, China, ⁶Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China

Keywords: lung cancer, Platinum complex, Water solubility, ROS/p53 pathway, cisplatin resistance

A Corrigendum on

Diplatin, a Novel and Low-Toxicity Anti-Lung Cancer Platinum Complex, Activation of Cell Death in Tumors via a ROS/JNK/p53-Dependent Pathway, and a Low Rate of Acquired Treatment Resistance

by Lin, X., Jia, Y., Dong, X., Shen, J., Jin, Y., Li, Y., Wang, F., Anenberg, E., Zhou, J., Zhu, J., Chen, X., Xie, Q., Xie, Y. (2019). *Front. Pharmacol.* 10:982. doi: 10.3389/fphar.2019.00982

In the original article, there was a mistake in **Figure 3H** as published. An incorrect image for the p53 measurement in A549 was shown. The corrected **Figure 3H** appears below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Lin, Jia, Dong, Shen, Jin, Li, Wang, Anenberg, Zhou, Zhu, Chen, Xie and Xie. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.




FIGURE 3 | JNK/p53-mediated pathway is involved in diplatin-induced apoptosis of tumor cells. **(H)** Pretreatment (0.5 h) with 10 μM JNK inhibitor (SP600125) suppresses the 48 h time point 25 μM diplatin-induced p53, Fas, and Bax protein upregulation (*n* = 4 per group). The data are presented as mean ± SEM from three independent experiments, one-way ANOVA followed by the Student-Newman-Keuls test. Statistical significance is indicated by **p* < 0.05, ***p* < 0.01, and ****p* < 0.001 for comparison with control and #*p* < 0.05, ##*p* < 0.01 for comparison with the diplatin-treated group.